Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations

• Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN , Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to access $150 million of the $250 million of commitments for new financing it received from certain of its creditors, as well as new borrowing availability from lenders under its asset-based loans.
• 08/30/2023

NYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)

• NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Ordinary Shares of Mallinckrodt plc (the “Company”) — ticker symbol MNK — from NYSE American. Trading in the Company's Ordinary Shares will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Section 1003(c).
• 08/28/2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK

• NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-03662, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Mallinckrodt securities between June 17, 2022 and June 14, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
• 08/28/2023

Mallinckrodt discloses grand jury subpoena, makes bankruptcy filing official

• Mallinckrodt PLC made it official Monday, with the Dublin, Ireland-based drugmaker filing for bankruptcy for the second time in three years after struggling to make settlement payments for its role in the opioid crisis.
• 08/28/2023

Drugmaker Mallinckrodt files for second bankruptcy in the US

• Drugmaker Mallinckrodt on Monday said the company and some of its units have filed for a second bankruptcy in 3 years in the U.S., with the newest restructuring plan set to reduce its debt by about $1.9 billion.
• 08/28/2023

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

• Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of the Company's first and second lien debtholders and the Opioid Master Disbursement Trust II (the "Trust"), as announced on August 23, 2023. Pursuant to the RSA and with the authorization of the Company's Board of Directors, Mallinckrodt and certain of its subsidiaries 1  today initiated voluntary prepackaged Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware.
• 08/28/2023

MALLINCKRODT SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Options

• NEW YORK , Aug. 26, 2023 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Mallinckrodt stock or options between June 17, 2022 and June 14, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.
• 08/26/2023

Mallinckrodt stock tumbles on plans to file for Chapter 11 bankruptcy for second time in three years

• Mallinckrodt PLC (NYSE:MNK) said it plans to initiate voluntary prepackaged Chapter 11 bankruptcy proceedings in the US in a matter of days to give it room to restructure its debt and reduce the amount it owes to opioid victims. Its shares fell 18% to $0.48 shortly before midday in New York, taking their year-to-date loss to 94%.
• 08/23/2023

MNK Stock Alert: Mallinckrodt Files for Bankruptcy Again

• Mallinckrodt (NYSEMKT: MNK ) stock isn't doing so hot on Wednesday after the pharmaceutical company gets ready for another bankruptcy filing. A press release from Mallinckrodt notes that it's going to file for bankruptcy in the coming days.
• 08/23/2023

U.S. drugmaker Mallinckrodt plans to file for bankruptcy protection

• Mallinckrodt is planning to start bankruptcy proceedings in the coming days, the U.S. drugmaker said on Wednesday, as it struggles to make required settlement payments for lawsuits alleging that it helped fuel the U.S. opioid crisis.
• 08/23/2023

Mallinckrodt to file for prepackaged Chapter 11 bankruptcy and cut about $1.9 billion in debt

• Mallinckrodt PLC MNK, +5.09% said Wednesday it has entered a Restructuring Support Agreement with most of its first and second lien debtholders and the Opioid Master Disbursement Trust II on the terms of a restructuring that will see it reduce its debt by about $1.9 billion. The agreement includes a final payment of $250 million to the Trust, on top of the $450 million already paid, to support its work on the opioid crisis and to fund addiction programs.
• 08/23/2023

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

• Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success  Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN , Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructuring Support Agreement ("RSA") with a substantial majority of each of the Company's first and second lien debtholders and the Opioid Master Disbursement Trust II (the "Trust") on the terms of a comprehensive financial restructuring plan that will reduce the Company's total funded debt by approximately $1.9 billion, increase free cash flow generation, extend maturity runway and better position the business for long-term success. The RSA also provides for, among other consideration, a final payment of $250 million to the Trust, in addition to the $450 million previously paid, to support the Trust's mission to address the U.S. opioid crisis and fund addiction treatment.
• 08/23/2023

MNK Investors Have Opportunity to Lead Mallinckrodt plc Securities Fraud Lawsuit

• LOS ANGELES , Aug. 22, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK). Class Period: June 17, 2022 – June 14, 2023 Lead Plaintiff Deadline: September 5, 2023 If you wish to serve as lead plaintiff of the Mallinckrodt lawsuit, you can submit your contact information at www.glancylaw.com/cases/Mallinckrodt-plc-1/.
• 08/22/2023

Should You Buy Penny Stocks Right Now? 3 Reasons

• 2023 has unfolded as a pivotal year for investors and traders alike, specifically those keen on harnessing the potential of penny stocks. These stocks, often priced below $5, present unique opportunities and advantages in the world of finance.
• 07/27/2023

Drugmaker Mallinckrodt in talks with hedge funds to avoid opioid settlements - WSJ

• Drugmaker Mallinckrodt is talking to hedge funds about filing for bankruptcy and avoiding payments intended to help people addicted to opioids, the Wall Street Journal reported on Wednesday.
• 07/26/2023

Mallinckrodt stock rises after disclosure of another one-week delay in the $200 million opioid-settlement payment

• Shares of Mallinckrodt PLC MNK, +4.35% rose 5.5% in afternoon trading Friday, after the drugmaker disclosed that it will once again delay the $200 million opioid-settlement payment by a week, following discussions with the Opioid Master Disbursement Trust II. The payment was originally scheduled for June 16, but the company has kept delaying payment a week at a time, as its board of directors continues to hold talks with stakeholders about its capital position and financial obligations.
• 07/14/2023

Levi Strauss shares tumble on outlook cut, Mallinckrodt and Alibaba shares rise and more stocks on the move

• Mallinckrodt PLC shares MNK, -5.26% surged 9% in the premarket trading after the drug maker and distributor said it was open to proposed transactions from debt holders as it keeps delaying a payment under an opioid settlement.
• 07/07/2023

Mallinckrodt open to proposed transactions as it struggles to pay opioid settlement; stock rallies

• Mallinckrodt PLC MNK shares surged in the extended session Thursday after the Dublin-based drug maker and distributor said it was open to proposed transactions as it keeps delaying a payment under an opioid settlement. Shares rallied as much as 15%, and were last up around 9% in late Thursday activity, following a 5.3% decline top close Thursday at $1.08 a share.
• 07/06/2023

Mallinckrodt makes late interest payment

• Drug maker Mallinckrodt MNK, on Monday said it paid roughly $17 million in interest that was due last Tuesday, as it tries to keep up with bill payments following a $1.7 billion opioid settlement following allegations it helped fuel the nation's opioid crisis. The payment, Mallinckrodt said, arrived within a grace period of five business days, keeping a default at bay.
• 06/26/2023

Mallinckrodt delays $200 million opioid-settlement payment by another week

• Mallinckrodt PLC MNK, -15.69% disclosed Friday that it has decided to further delay the $200 million opioid-settlement payment by a week. The payment was originally due on June 16, before payment was delayed to June 23, and is now delayed to June 30.
• 06/23/2023

Mallinckrodt readies retention bonuses in event of bankruptcy filing

• Generic-drug maker Mallinckrodt MNK, +17.69% on Wednesday said it set aside more than $3.4 million in executive retention bonuses in the event of a possible filing for yet another bankruptcy. The move is latest sign of difficulty for the company, which has struggled to pay its bills in the wake of a $1.7 billion opioid settlement following allegations it helped propel the nation's opioid crisis.
• 06/21/2023

Mallinckrodt stock soars, after disclosure that $200 million opioid-settlement payment was delayed by a week

• Shares of Mallinckrodt PLC MNK, +24.14% shot up 26.5% in afternoon trading, after the drug maker said it reached an agreement to delay a $200 million opioid-settlement payment by a week. The stock's rally comes after it closed Thursday below the $1 mark for the first time, at 87 cents.
• 06/16/2023

Mallinckrodt looking to delay $200 million opioid payment - Bloomberg News

• Mallinckrodt is seeking to postpone a $200 million opioid settlement payment, Bloomberg News reported on Thursday citing people with knowledge of the matter.
• 06/15/2023

Mallinckrodt stock falls after decision not to make interest payments, as drug maker continues to mull potential bankruptcy

• Shares of Mallinckrodt PLC MNK dropped 4.8% in premarket trading Thursday, after the drug maker disclosed that it decided not to make interest payments that were due on June 15 on two senior secured notes. The company said failing to make the interest payments would constitute and event of default if the failure continues for a period of 30 days, for both the 11.50% First Lien Senior Secured Notes due 2028 and the 10.00% Second Lien Senior Secured Notes due 2029.
• 06/15/2023

Why Is Mallinckrodt (MNK) Stock Down 23% Today?

• Mallinckrodt (NYSEMKT: MNK ) stock is falling hard on Monday after the company received letters from concerned noteholders. These letters have holders of notes due in 2027 and 2029 expressing issues with the company's current financial situation.
• 06/05/2023

Mallinckrodt evaluating another possible bankruptcy filing as $200 million opioid settlement pay comes due

• Shares of Mallinckrodt PLC MNK, -5.41% tumbled 22.0% in premarket trading Monday, after the drug maker disclosed that certain debt holders proposed another bankruptcy filing given the company's financial position. The proposal comes as the company is required to make a $200 million payment on June 16, as part of its opioid settlement.
• 06/05/2023

Drugmaker Mallinckrodt says lenders propose another bankruptcy filing

• Drugmaker Mallinckrodt plc said on Monday some of its lenders have proposed that the company consider another bankruptcy filing as it nears a deadline to pay a $200 million opioid settlement.
• 06/05/2023

Drugmaker Mallinckrodt may file for bankruptcy again -WSJ

• Pharmaceutical company Mallinckrodt Plc is considering options including filing for bankruptcy again as a $200 million opioid settlement payment is due within weeks, the Wall Street Journal reported on Friday citing people familiar with the matter.
• 06/02/2023

Mallinckrodt to Report Earnings Results for First Quarter 2023

• DUBLIN , April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.  A conference call for investors will begin at 8:30 a.m.
• 04/24/2023

Mallinckrodt plc (MNK) Q4 2022 Earnings Call Transcript

• Mallinckrodt plc (NYSE:MNK ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller and Chief Investor Relations Officer Sigurdur Olafsson - President and Chief Executive Officer Bryan Reasons - Executive Vice President and Chief Financial Officer Conference Call Participants Rishi Parekh - JP Morgan Brendan Hall - Brean Asset Management LLC Operator Good day, and thank you for standing by. Welcome to the Mallinckrodt Q4 2022 Earnings Announcement.
• 02/28/2023

Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference

• DUBLIN , Feb. 16, 2023 /PRNewswire/ --  Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen's 43rd Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2023 at 2:50 p.m. Eastern Time.
• 02/16/2023

Mallinckrodt to Report Earnings Results for Fourth Quarter 2022

• DUBLIN , Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023.  A conference call for investors will begin at 8:30 a.m.
• 02/08/2023

Mallinckrodt Will Likely Survive The Opioid Claims And Litigations

• Mallinckrodt develops and markets specialty pharmaceutical products for autoimmune and rare diseases. In my view, investors really forgot about the potential future free cash flow that Mallinckrodt could generate.
• 11/11/2022

Mallinckrodt plc (MNK) Q3 2022 Earnings Call Transcript

• Mallinckrodt plc (NYSE:MNK ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller & Chief IR Officer Sigurdur Olafsson - President & CEO Bryan Reasons - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Mallinckrodt Third Quarter Earnings Annual Announcement.
• 11/08/2022

Mallinckrodt plc (MNK) CEO Sigurdur Olafsson on Q2 2022 Results - Earnings Call Transcript

• Mallinckrodt plc (NYSE:MNK ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller & Chief IR Officer Sigurdur Olafsson - President & CEO Bryan Reasons - Chief Financial Officer Conference Call Participants Gregory Fraser - Truist Securities David Amsellem - Piper Sandler Operator Good morning, and welcome to the Mallinckrodt Q2 2022 Earnings Announcement and Business Update Conference Call. All participants will be in listen-only mode.
• 08/11/2022

How To Predict Sales Growth

• I've found seven factors that correlate highly with future sales growth; this article explains each one.
• 09/08/2020

Wall Street Breakfast: The Week Ahead

• Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
• 09/06/2020

Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop

• Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
• 09/05/2020

Mallinckrodt Is Just Too Complex For My Liking

• Mallinckrodt has two upcoming approvals, a $126mn market cap, $818mn in cash, and a whopping $5.24bn in debt.
• 09/03/2020

Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma

• Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation. Calliditas Therapeutics inks deal for Genkyotex Acquisition.
• 08/16/2020

Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Stratatech Biologics License Application (BLA) for StrataGraft®, an investigational regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The FDA granted the application priority review and assigned a Prescription Drug User Fee Act (PDUFA) target date of February 2, 2021.
• 08/10/2020

Were Hedge Funds Right About Ditching Mallinckrodt Public Limited Company (MNK)?

• We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
• 08/05/2020

Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates

• Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
• 08/05/2020

Stocks on the Move: Mallinckrodt, Ralph Lauren

• Today's Stocks on the Move: Mallinckrodt, Ralph Lauren
• 08/04/2020

Mallinckrodt Stock Sinks After the Drugmaker Said It Might File for Bankruptcy

• Its headline second-quarter earnings results were better than expected. But it is struggling with more than 2,500 lawsuits over its opioid sales and other issues.
• 08/04/2020

Mallinckrodt (MNK) Beats Q2 Earnings and Revenue Estimates

• Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
• 08/04/2020

Mallinckrodt stock plunges after talks regarding possible bankruptcy filing, offsetting adjusted profit beat

• Shares of Mallinckrodt PLC plunged 25% in premrket trading Tuesday, reversing an earlier gain, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted profit that beat expectations, while disclosing talks with creditors and litigation claimants regarding the possibility of a bankruptcy filing. The company reported a net loss of $933.1 million, or $11.04 a share, after net income of $6.8 million, or 8 cents a share, in the year-ago period. Excluding non-recurring items, such as a one-time Acthar Gel Medicaid rebate liability of $639.7 million, adjusted earnings per share came to $1.89, above the FactSet consensus of $1.34. Net sales fell to $166.5 million from $823.3 million. A one-time Acthar Gel Medicaid liability lowered sales by $534.4 million. In its business and litigation update, the company stated: "Due to pressures from the Acthar Gel Medicaid matter, the ongoing opioid litigation and the Company's existing debts and the related risk of non-compliance with its financial debt covenant over the next twelve months, the Company has been working with external advisors to explore a range of options and engage in dialogue with financial creditors and litigation claimants and their advisors, including the possibility of a filing for reorganization in bankruptcy under Chapter 11 by Mallinckrodt PLC and most of its subsidiaries in the near-term." The company said its cash balance at the end of the second quarter was $818.3 million and the revolving credit facility was fully drawn, while total principal debt outstanding was $5.29 billion. The stock has tumbled 31.5% over the past three months through Monday, while the S&P 500 has climbed 15.9%.
• 08/04/2020

Recap: Mallinckrodt Q2 Earnings

• Shares of Mallinckrodt (NYSE:MNK) decreased 24% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 25.30% over the past year to $1.89, which beat the estimate of $1.35.Revenue of $700,900,000 decreased by 14.87% year over year, which beat the estimate of $635,330,000.Guidance Earnings guidance hasn't been issued by the company for now.Mallinckrodt hasn't issued any revenue guidance for the time being.Details Of The Call Date: Aug 04, 2020View more earnings on MNKTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/q3neeh49Technicals Company's 52-week high was at $6.87Company's 52-week low was at $1.00Price action over last quarter: down 25.17%Company Overview Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands that includes innovative specialty pharmaceutical brands; and Specialty Generics that includes niche specialty generic drugs and active pharmaceutical ingredients.See more from Benzinga * 52 Stocks Moving In Wednesday's Regular-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
• 08/04/2020

Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline Advancements

• Second quarter net sales of $166.5 million net of the retrospective one-time Acthar
• 08/04/2020

Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again

• Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
• 07/30/2020

Earnings Preview: Mallinckrodt (MNK) Q2 Earnings Expected to Decline

• Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 07/28/2020

Top Ranked Growth Stocks to Buy for July 24th

• Top Ranked Growth Stocks to Buy for July 24th
• 07/24/2020

Are Options Traders Betting on a Big Move in Cameco Mallinckrodt (MNK) Stock?

• Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
• 07/20/2020

Stocks To Watch: Vaccine Players, Earnings Blitz And Fiscal Debate

• Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
• 07/18/2020

FDA Advisory Committee Recommends Mallinckrodt's Trelipressin

• The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
• 07/16/2020

The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO

• Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) * Atossa Therapeutics Inc (NASDAQ: ATOS) (announced results from lab studies of AT-301, its COVID-19 nasal spray drug candidate) * AstraZeneca plc (NYSE: AZN) (moved on reports that it could issue an update on its coronavirus vaccine program soon) * Beigene Ltd (NASDAQ: BGNE) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * Castle Biosciences Inc (NASDAQ: CSTL) (announced publication of a study demonstrating its DecisionDx-UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma) * Catalent Inc (NYSE: CTLT) * Cytokinetics, Inc. (NASDAQ: CYTK) (issued an investor update on its cardiovascular pipeline) * ESSA Pharma Inc (NASDAQ: EPIX) (announced enrollment of first patient in Phase 1 study of its prostate cancer drug) * Genetic Technologies Limited (NASDAQ: GENE) (issued an update on its COVID-19 Severity Risk Test) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Heat Biologics Inc (NASDAQ: HTBX) * Hologic, Inc. (NASDAQ: HOLX) * Inspire Medical Systems Inc (NYSE: INSP) * Moderna Inc (NASDAQ: MRNA) * Novavax, Inc. (NASDAQ: NVAX) * OncoSec Medical Inc (NASDAQ: ONCS) * Qiagen NV (NYSE: QGEN) * ResMed Inc. (NYSE: RMD) * Principia Biopharma Inc (NASDAQ: PRNB) * Sanofi SA (NASDAQ: SNY) * TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) * Trevena Inc (NASDAQ: TRVN) * Twist Bioscience Corp (NASDAQ: TWST) * VBI Vaccines Inc (NASDAQ: VBIV) * West Pharmaceutical Services Inc. (NYSE: WST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 15) * Endologix, Inc. (NASDAQ: ELGX) * immatics biotechnologies GmbH (NASDAQ: IMTX) * Repare Therapeutics Inc (NASDAQ: RPTX)Stocks In Focus FDA Communicates Deficiencies In Tricida's NDA For Metabolic Acidosis Drug Tricida Inc (NASDAQ: TCDA) said it has received a notification from the FDA stating that, as part of its ongoing review of its New Drug Application for veverimer in metabolic acidosis, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. The PDUFA date is scheduled for Aug. 22."We continue to believe in the potential of veverimer to be disease modifying and our goal is to work with FDA to identify and resolve the issues in order to bring veverimer to patients," the company said in the release.The stock was down 32.6% at $17.66 premarket Thursday.Mallinckrodt's Hepatorenal Disease Drug Backed By FDA Panel In Tight Vote Mallinckrodt PLC (NYSE: MNK) said FDA's Cardiovascular and Renal Drugs Advisory Committee voted to recommend approval for its investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 by an 8-7 vote. HRS-1 is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.Mallinckrodt shares were up 2.58% at $3.18 premarket Thursday.Nabriva to Distribute Merck's Antibiotics In US Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) said it has as entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., (NYSE: MRK) to distribute Sivextro in the U.S. and certain of its territories through Dec. 31, 2023, with renewable three-year extensions. Sivextro is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 and older for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible gram-positive microorganisms.The stock jumped 63.91% to $1.09 premarket. See also: The Week Ahead In Biotech: J&J; Kickstarts Pharma Earnings, Relay Therapeutics IPO CytoDyn Applies For Uplisting To Nasdaq CytoDyn Inc (OTCQB: CYDY) said it has filed a comprehensive listing application package with the Nasdaq to request an uplisting of its common stock. The company said it believes it satisfies the initial listing requirements for the exchange.The stock edged down 0.58% to $5.10 in after-hours trading.I-Mab To Buy Back Up To $20M In Shares I-Mab ADR (NASDAQ: IMAB) said its board has authorized a stock repurchase program to buy up to $20 million in ordinary shares in the form of ADSs.Novartis To Make Not-for-Profit Medicine Portfolio Available At Zero Cost Novartis AG (NYSE: NVS) announced a new initiative to help patients in low-income and lower-middle-income countries access affordable medicines to treat the major symptoms of COVID-19.The company said it will make the drugs available to governments, NGOs and other institutional customers in up to 79 eligible countries at zero profit.The COVID-19 portfolio includes 15 medicines from its Sandoz division for gastrointestinal illness, acute respiratory symptoms, pneumonia and septic shock.Offerings INmune Bio Inc (NASDAQ: INMB), which announced a positive Alzheimer's drug readout earlier this week, said it has commenced an underwritten public offering of shares of its common stock.View more earnings on IBBThe stock was down 18.01% at $10.70 premarket. Aptose Biosciences Inc (NASDAQ: APTO) said it has commenced an underwritten public offering of its common shares. All the shares to be sold in the proposed offering will be sold by the company. The company said it intends to use the net proceeds to accelerate clinical trials of CG-806 and APTO-253, acquire additional clinical assets and for working capital and general corporate purposes.The stock was down 10.38% at $5.61 premarket. Cytokinetics announced plans to offer, subject to market and other conditions, $150 million in common stock in an underwritten public offering. All of the shares of common stock in the offering will be sold by the company.The stock slid 3.31% to $28 premarket. Atreca Inc (NASDAQ: BCEL) said it has priced its previously announced underwritten public offering of 7.03125 million shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock, each at a price of $16 per share. The company expects the offering to raise gross proceeds of $125 million, with the offering slated to close on or about July 20.In premarket trading, the stock was down 14.77% at $15.70.On The Radar Earnings * Abbott Laboratories (NYSE: ABT) (before the market open) * AngioDynamics, Inc. (NASDAQ: ANGO) (before the market open) * Johnson & Johnson (NYSE: JNJ) (before the market open)IPOs Cambridge, Massachusetts-based Relay Therapeutics priced its upsized offering of 20 million shares at $20, above the estimated price range of $16-$18, for raising gross proceeds of $400 million.Relay is a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The shares will begin trading on the Nasdaq under the ticker symbol "RLAY."Related Link: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates See more from Benzinga * The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent * The Daily Biotech Pulse: Blueprint, Roche Ink .7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
• 07/16/2020

Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval for its investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 (HRS-1) (8 yes; 7 no). HRS-1 is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 Terlipressin is an investigational agent being evaluated for the treatment of HRS-1 in the U.S., and its safety and effectiveness have not yet been established by the FDA.
• 07/15/2020

Stocks To Watch: Bank Earnings And SPAC Deals Blaze In

• Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
• 07/11/2020

Mallinckrodt to Report Earnings Results for Second Quarter 2020

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report second quarter 2020 earnings results for the period ended June 26, 2020 on Tuesday, Aug. 4, 2020.
• 07/09/2020

FDA Advisory Committee to Review Mallinckrodt'sTerlipressin

• Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.
• 07/08/2020

Mallinckrodt Confirms that U.S. Food and Drug Administration (FDA) Will Convene an Advisory Committee to Review Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will, as expected, hold a virtual meeting to review data on terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 (HRS-1). The company announced the FDA accepted for review its New Drug Application (NDA) for terlipressin in April.
• 07/07/2020

Hedge Funds Never Been Less Bullish On Mallinckrodt Public Limited Company (MNK)

• In this article you are going to find out whether hedge funds think Mallinckrodt Public Limited Company (NYSE:MNK) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus […]
• 06/23/2020

Beyond Air: COVID-19 And More

• A presentation in March caused XAIR to sell off, many snapped up the buying opportunity but the name is still below early-March highs. Updates provided on the d
• 06/23/2020

Opioid Actions in New York State Bode Ill for Mallinckrodt, Says Citi

• “Opioid risk is coming back,” says analyst Navann Ty, who lowered her rating on the drugmaker to Sell in the face of a lawsuit and a separate investigation by the state.
• 06/17/2020

Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference. Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors. A replay of the fireside chat will also be available following the meeting.
• 06/17/2020

Mallinckrodt to Proceed with Appeal Despite Appellate Court Decision Denying Temporary Injunction in Ongoing Acthar Gel Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced its disappointment with the U.S. Court of Appeals for the District of Columbia decision to deny its request for a temporary injunction preventing the U.S. Centers for Medicare and Medicaid Services (CMS) from enforcing a change in Medicaid drug rebate calculation for Acthar® Gel (repository corticotropin injection). Mallinckrodt had asked for the temporary injunction as it appeals a lower court ruling that allowed CMS to reset the base date average manufacturer price (AMP). The Appeals Court also ordered an expedited briefing and oral argument schedule that will likely lead to fall oral arguments, and potentially a ruling by end of year.
• 06/15/2020

Mallinckrodt to Present Phase 3 StrataGraft® Regenerative Skin Tissue Clinical Trial Results on Severe Burns During the Virtual American Burn Association 52nd Annual Meeting

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data from the pivotal Phase 3 clinical trial (STRATA2016) of its investigational product StrataGraft®, a regenerative skin tissue therapy in development for the treatment of deep partial-thickness thermal burns, as well as health economics and outcomes research (HEOR) and other data on the treatment of burns as part of the virtual American Burn Association (ABA) 52nd Annual Meeting. The virtual meeting begins today and is accessible online for attendees during the next 90 days. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration (FDA).
• 06/15/2020

Edited Transcript of MNK earnings conference call or presentation 5-May-20 12:30pm GMT

• Q1 2020 Mallinckrodt Plc Earnings Call
• 06/13/2020

Mallinckrodt Highlights Publication Of Findings From Medical Chart Study To Assess Use Of Terlipressin, Other Vasopressors In Hospitalized Patients With Hepatorenal Syndrome Type 1

• 06/11/2020

Real-World Data of Terlipressin in Hospitalized Patients in U.K. with Hepatorenal Syndrome Type 1 (HRS-1) Published in Alimentary Pharmacology and Therapeutics

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors in hospitalized patients with hepatorenal syndrome type 1 (HRS-1), an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 The study, funded by Mallinckrodt, found that terlipressin was associated with an improvement in kidney function among HRS-1 patients as measured by a reduction in serum creatinine (SCr). The results of the study were published in the peer-reviewed journal Alimentary Pharmacology and Therapeutics.
• 06/11/2020

Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue

• Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns
• 06/10/2020

Mallinckrodt Completes Rolling Submission Of Biologics License Application For Stratagraft Regenerative Skin Tissue To FDA

• 06/09/2020

Mallinckrodt Completes Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has completed its rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for StrataGraft®, a regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The company previously announced initiation of the rolling submission in April. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been established by the FDA.
• 06/09/2020

Why Is Mallinckrodt (MNK) Down 5.8% Since Last Earnings Report?

• Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
• 06/04/2020

Implied Volatility Surging for Mallinckrodt (MNK) Stock Options

• Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
• 06/01/2020

Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services

• 06/01/2020

Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will appeal a ruling by the U.S. District Court for the District of Columbia in a lawsuit filed by its subsidiary, Mallinckrodt ARD LLC, against the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS), regarding the Medicaid drug rebate calculation for Acthar® Gel (repository corticotropin injection).
• 06/01/2020

Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug ...

• 06/01/2020

2 Pharmaceutical Stocks Trading Below Their Book Value

• Frequently, buying stocks trading below their fundamental net worth can yield lucrative rewards for investors.
• 05/31/2020

Dow ends 390 points lower after report cast doubt on Moderna’s coronavirus vaccine candidate

• U.S. stocks lost ground in the final hour of trade Tuesday, reversing earlier gains, following at a critical report of Moderna’s vaccine candidate and congressional testimony on progress toward delivering federal aid.
• 05/19/2020

Mallinckrodt shares are trading lower after JP Morgan downgraded the company's stock from Neutral to Underweight.

• 05/19/2020

JP Morgan Downgrades Mallinckrodt to Underweight

• 05/19/2020

Top 3 Contrarian Stocks to Buy Right Now

• Indiscriminate sell-offs can sometimes lead to opportunities the crowds have missed. Here are three stocks that fit the criteria.
• 05/15/2020

Centerbridge Partners, L.P. Buys iShares iBoxx $ Investment Grade Corporate Bond, Surgery ...

• 05/15/2020

New York Ag Says Will Issue New Subpoenas To Multiple Banks, Financial Institutions To Determine Where The Sacklers Stored Their Money Over The Years

• 05/13/2020

Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss

• Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
• 05/06/2020

SVB Leerink Maintains Market Perform on Mallinckrodt, Raises Price Target of $3

• 05/06/2020

Edited Transcript of MNK earnings conference call or presentation 5-May-20 12:30pm GMT

• Q1 2020 Mallinckrodt Plc Earnings Call
• 05/06/2020

Mallinckrodt (MNK) Q1 2020 Earnings Call Transcript

• Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Mallinckrodt earnings conference call. Joining me this morning are Mark Trudeau, CEO; Steven Romano, our chief scientific officer; and Bryan Reasons, our CFO.
• 05/06/2020

Why Mallinckrodt Stock Tumbled Today

• Investors were disappointed by the company's Q1 results and the prospects of continued challenges from the COVID-19 pandemic.
• 05/05/2020

Mallinckrodt (MNK) Q1 Earnings Surpass Estimates

• Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.31% and -2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
• 05/05/2020

Mallinckrodt shares are trading lower the company reported worse-than-expected Q1 sales.

• 05/05/2020

Recap: Mallinckrodt Q1 Earnings

• Shares of Mallinckrodt (NYSE:MNK) were unchanged in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 15.46% over the past year to $1.64, which beat the estimate of $1.48.Revenue of $665,800,000 less by 15.79% year over year, which missed the estimate of $693,310,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 05, 2020View more earnings on MNKWebcast URL: https://edge.media-server.com/mmc/p/u396hdtkPrice Action 52-week high: $17.4052-week low: $1.00Price action over last quarter: down 16.03%Company Description Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands that includes innovative specialty pharmaceutical brands; and Specialty Generics that includes niche specialty generic drugs and active pharmaceutical ingredients.See more from Benzinga * 16 Healthcare Stocks Moving In Monday's Pre-Market Session * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
• 05/05/2020

Mallinckrodt Q1 Adj. EPS $1.640 Beats $1.480 Estimate, Sales $665.800M Miss $693.310M Estimate

• 05/05/2020

Mallinckrodt plc Reports Earnings for the First Quarter 2020 and Highlights Pipeline Progress

• First quarter net sales of $665.8 million, with diluted loss per share of $0.60, with results impacted in part by competitive and payer pressures in certain products and a decline in demand due to COVID-19
• 05/05/2020

Mallinckrodt's INOmax Study Ended Early Due to Achievement of its Primary Goal

• 05/04/2020

Mallinckrodt Announces Positive Findings in INOmax® (Nitric Oxide) Gas, for Inhalation Phase 4 Observational Registry in Neonates with Pulmonary Hypertension; Ends Trial Early

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that its observational registry comparing the safety and effectiveness of INOmax® (nitric oxide) gas, for inhalation, in term and near-term neonates to that in preterm neonates with pulmonary hypertension (PH) was ended early due to achievement of the pre-specified primary outcome measure, non-inferiority (95 percent confidence interval: -0.0021, 0.1158, with a pre-defined margin of -0.1452). The decision was made following the second planned interim analysis at 75 percent enrollment. The company intends to share the results of this study in an appropriate scientific forum soon.
• 05/04/2020

Mallinckrodt Announces Positive Findings in INOmax® (Nitric Oxide) Gas, for Inhalation Phase 4 ...

• 05/04/2020

Will an Opioid Manufacturer Stage a Comeback With This New Venture?

• A billion-dollar market opportunity exists for an opioid manufacturer plagued with lawsuits, but will it be enough for a comeback?
• 05/01/2020

Mallinckrodt (NYSE:MNK) Shares Gap Up to $3.88

• Mallinckrodt PLC (NYSE:MNK)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $3.76, but opened at $3.88. Mallinckrodt shares last traded at $3.88, with a volume of 6,469,600 shares trading hands. Several research analysts recently issued reports on MNK shares. Bank of America increased their target price on […]
• 05/01/2020

Mallinckrodt to fund trial to test nitric oxide therapy in COVID-19 patients

• 04/30/2020

2 more Ohio counties to be subject of another opioid trial

• A judge has added claims from two Ohio counties against pharmacies to the growing list of trials on governments' claims that the drug industry should be held liable for the U.S. opioid epidemic. U.S. District Court Judge Dan Polster ruled Thursday that Lake and Trumbull counties should be the plaintiffs in a test case to be tried in his Cleveland courtroom in May 2021. At issue will be both pharmacy chains' roles in distributing powerful prescription painkillers to their own stores and dispensing them to patients. Both pharmacy roles were set to be included in a trial scheduled for November 2020 regarding claims from two other Ohio counties — Cuyahoga and Summit. But an appeals court sided with pharmacy chains and found Polster improperly included the drug dispensing role in that one. Polster responded by adding that the companies will face an additional trial with a broader range of claims. It's not certain yet which companies would be defendants, but those involved in the suits so far are CVS, Discount Drug Mart, Giant Eagle, Rite Aid, Walgreens and Walmart. Prescription opioids such as OxyContin and Vicodin and illicit versions such as heroin and illegally produced fentanyl have been linked to more than 430,000 deaths in the U.S. since 2000. So far, there has been just one trial in the U.S. to test the liability of the drug industry for the epidemic. In that one, a judge last year ruled Johnson & Johnson and its subsidiaries had to pay the state of Oklahoma $465 million. The company is appealing. Companies have settled other claims before they reached trial, including one that was scheduled before Polster last year. The next trial in line could be a case in New York state case that was scheduled to start this month but was delayed because of the coronavirus...
• 04/30/2020

2 more Ohio counties to be subject of another opioid trial

• A judge has added claims from two Ohio counties against pharmacies to the growing list of trials on governments' claims that the drug industry should be held liable for the U.S. opioid epidemic. U.S. District Court Judge Dan Polster ruled Thursday that Lake and Trumbull counties should be the plaintiffs
• 04/30/2020

Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it is supporting an investigator-initiated clinical study at Massachusetts General Hospital evaluating the potential benefits of inhaled nitric oxide as a treatment for pulmonary complications in patients infected with COVID-19. Mallinckrodt's support to Massachusetts General Hospital includes providing funding as well as INOmax® (nitric oxide) gas, for inhalation, to facilitate the study.
• 04/30/2020

Mallinckrodt to fund trial to test nitric oxide therapy in COVID-19 patients

• Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung complications in …
• 04/30/2020

Mallinckrodt to fund trial to test nitric oxide therapy in COVID-19 patients

• Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung complications in patients infected with the new coronavirus.
• 04/30/2020

Mallinckrodt Says Is Supporting Investigator-Initiated Study At Massachusetts General Hospital To Assess Effectiveness Of Inhaled Nitric Oxide In Patients With Severe Acute Respiratory Distress Syndrome Due To COVID-19

• 04/30/2020

Beirne Wealth Consulting Services LLC Increases Stake in Mallinckrodt PLC (NYSE:MNK)

• Beirne Wealth Consulting Services LLC increased its position in Mallinckrodt PLC (NYSE:MNK) by 44.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 32,500 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. Beirne Wealth Consulting Services LLC’s holdings in […]
• 04/29/2020

Mallinckrodt (NYSE:MNK) Rating Lowered to Strong Sell at ValuEngine

• Mallinckrodt (NYSE:MNK) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Wednesday, ValuEngine reports. Several other research firms also recently issued reports on MNK. Barclays reduced their price target on shares of Mallinckrodt from $5.00 to $3.00 and set an “equal weight” rating for the company […]
• 04/29/2020

Aurinia Taps Cerecor's Miller to Succeed Retiring Chief Financial Officer

• Aurinia Pharmaceuticals (NASDAQ: ]) announced that Joe Miller would become its new chief financial officer, succeeding Dennis Bourgeault, who is retiring
• 04/28/2020

Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for

• Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 04/28/2020

Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for

• Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 04/28/2020

Global and Chinese Market for Paracetamol 2020, with Company Profiles of Key Players Including Mallinckrodt, Farmson and SPI Pharma

• Dublin, April 28, 2020 -- The "Paracetamol Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology,.
• 04/28/2020

Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for

• 04/28/2020

Aurinia Appoints Joe Miller as Chief Financial Officer

• – Dennis Bourgeault to retire after more than 20 years with the company –VICTORIA, British Columbia & ROCKVILLE, Md. — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia…
• 04/27/2020

Aurinia Appoints Joe Miller as Chief Financial Officer

• Aurinia Appoints Joe Miller as Chief Financial Officer
• 04/27/2020

Mallinckrodt PLC Forecasted to Post FY2020 Earnings of $5.37 Per Share (NYSE:MNK)

• Mallinckrodt PLC (NYSE:MNK) – Research analysts at SVB Leerink lowered their FY2020 earnings per share estimates for shares of Mallinckrodt in a note issued to investors on Thursday, April 23rd. SVB Leerink analyst A. Fadia now expects that the company will earn $5.37 per share for the year, down from their previous estimate of $5.69. […]
• 04/27/2020

Bank of New York Mellon Corp Decreases Holdings in Mallinckrodt PLC (NYSE:MNK)

• Bank of New York Mellon Corp decreased its stake in Mallinckrodt PLC (NYSE:MNK) by 60.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 365,828 shares of the company’s stock after selling 552,247 shares during the quarter. Bank of New York Mellon […]
• 04/25/2020

Mallinckrodt PLC (NYSE:MNK) Given Consensus Recommendation of "Hold" by Brokerages

• Shares of Mallinckrodt PLC (NYSE:MNK) have been assigned an average rating of “Hold” from the eighteen analysts that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company. The average 1 […]
• 04/25/2020

PAVmed FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

• PAVmed's carpal tunnel syndrome device CarpX is approved. Prothena's Parkinson's study flops, taking the stock down. Mallinckrodt's kidney failure drug applicat
• 04/24/2020

Cerecor Announces Changes to Board of Directors

• Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Dr. Sol J. Barer has been appointed as the Chairman of the Board as Dr. Simon Pedder steps down as Executive Chairman
• 04/24/2020

Opioid Use Disorder Market to Soar at 10.8% CAGR till 2026; Increasing Research in Opioids by Pharmaceuticals to Aid Market Expansion: Fortune Business Insights™

• Pune, April 24, 2020 -- The global opioid use disorder market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period..
• 04/24/2020

Mallinckrodt initiated with a Sell at Citi MNK

• Mallinckrodt initiated with a Sell at Citi Citi MNK
• 04/24/2020

$697.45 Million in Sales Expected for Mallinckrodt PLC (NYSE:MNK) This Quarter

• Equities analysts predict that Mallinckrodt PLC (NYSE:MNK) will report sales of $697.45 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Mallinckrodt’s earnings, with the lowest sales estimate coming in at $653.01 million and the highest estimate coming in at $720.10 million. Mallinckrodt reported sales of $790.60 […]
• 04/24/2020

Mallinckrodt PLC (NYSE:MNK) Expected to Earn Q1 2020 Earnings of $1.32 Per Share

• Mallinckrodt PLC (NYSE:MNK) – Piper Sandler cut their Q1 2020 EPS estimates for Mallinckrodt in a research note issued to investors on Monday, April 20th. Piper Sandler analyst D. Amsellem now expects that the company will post earnings of $1.32 per share for the quarter, down from their previous forecast of $1.33. Piper Sandler also […]
• 04/23/2020

CMG, CLDX among premarket gainers

• SAExploration Holdings (NASDAQ:SAEX) +177% on $27M new project in Greece.B.O.S. Better Online Solutions (NASDAQ:BOSC) +56% on $1M order.The Peck Company Holdings (NASDAQ:PECK) +51% on partnership with
• 04/22/2020

BRIEF-Mallinckrodt Announces U.S. FDA Filing Acceptance Of New Drug Application Treatment Of Hepatorenal Syndrome

• Mallinckrodt Plc:
• 04/22/2020

• Farewell, Comfort. That’s one takeaway from Gov. Andrew Cuomo’s sitdown Tuesday with Donald Trump, where the president asked “Andrew” if New York would be willing to relinquish the Navy ship that was sent to New York City’s harbor now that the additi
• 04/22/2020

Mallinckrodt reports FDA acceptance of NDA for terlipressin MNK

• Mallinckrodt reports FDA acceptance of NDA for terlipressin MNK
• 04/22/2020

Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of New Drug Application for Terlipressin for Treatment of Hepatorenal Syndrome Type 1 (HRS-1)

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 (HRS-1). On March 17, 2020 the company announced the completion of its rolling submission of the NDA for terlipressin. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of September 12, 2020.
• 04/22/2020

Mallinckrodt shares are trading higher after the company announced the FDA has approved for review its New Drug Application for Terlipressin.

• 04/22/2020

New York charges Mallinckrodt with insurance fraud over opioid claims

• NEW YORK — New York state brought civil charges on Tuesday accusing Mallinckrodt Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically u…
• 04/21/2020

UPDATE 3-New York charges Mallinckrodt with insurance fraud over opioid claims

• New York state brought civil charges on Tuesday accusing Mallinckrodt Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.
• 04/21/2020

New York charges Mallinckrodt with insurance fraud over opioid claims

• New York state brought civil charges on Tuesday accusing Mallinckrodt Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.
• 04/21/2020

New York charges Mallinckrodt with insurance fraud over opioid claims

• NEW YORK — New York state brought civil charges on Tuesday accusing Mallinckrodt Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically u…
• 04/21/2020

New York charges Mallinckrodt with insurance fraud related to opioids

• New York state charged Mallinckrodt Plc on Tuesday with insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.
• 04/21/2020

UPDATE 1-New York charges Mallinckrodt with insurance fraud related to opioids

• (Adds allegations, stock price)
• 04/21/2020

New York charges Mallinckrodt with insurance fraud over opioid claims

• New York state brought civil charges on Tuesday accusing Mallinckrodt Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions. Governor Andrew Cuomo said the charges brought by New York's Department of Financial Services are the first against a major opioid manufacturer in the regulator's probe into entities that contributed to the nationwide opioid crisis. New York accused Mallinckrodt of overstating the benefits of long-term opioid treatment, downplaying the risks of addiction and abuse, and knowing its conduct would result in the payment of fraudulent insurance claims on unnecessary prescriptions.
• 04/21/2020

New York charges Mallinckrodt with insurance fraud related to opioids

• New York has charged Mallinckrodt Plc with insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.
• 04/21/2020

New York charges Mallinckrodt with insurance fraud related to opioids

• NEW YORK, April 21 (Reuters) - New York has charged Mallinckrodt Plc with insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions. Governor Andrew Cuomo said on Tuesday that the
• 04/21/2020

Stocks - Dow Down as Bears Sink Teeth Into Tech Amid Oil Plunge

• By Yasin Ebrahim
• 04/21/2020

IRIDEX Announces the Appointment of Doris Engibous to its Board of Directors

• IRIDEX Corporation (IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Doris Engibous to its board of directors effective April 20, 2020. The Company will also nominate Ms. Engibous for re-election
• 04/21/2020

Should You Buy This Biotech That Makes A Lower Risk Painkiller?

• A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.
• 04/21/2020

20,476 Shares in Mallinckrodt PLC (NYSE:MNK) Acquired by Golden State Wealth Management LLC

• Golden State Wealth Management LLC acquired a new position in shares of Mallinckrodt PLC (NYSE:MNK) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 20,476 shares of the company’s stock, valued at approximately $41,000. Other institutional investors also recently made changes to […]
• 04/21/2020

Mallinckrodt Shares Relatively Quiet But Saw Large Volume Spike; Hearing New York Governor Cuomo Says Initiated Admin. Proceedings, Filed Charges Against Co. Related To Opioid Crisis

• 04/21/2020

Mallinckrodt (NYSE:MNK) Downgraded by ValuEngine to Sell

• Mallinckrodt (NYSE:MNK) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Monday, ValuEngine reports. Other equities research analysts also recently issued reports about the company. Bank of America upped their price objective on Mallinckrodt to $3.00 and gave the company an “underperform” rating […]
• 04/20/2020

Mallinckrodt (NYSE:MNK) Shares Gap Down to $3.57

• Mallinckrodt PLC (NYSE:MNK)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $3.33, but opened at $3.57. Mallinckrodt shares last traded at $3.53, with a volume of 28,820 shares changing hands. MNK has been the topic of a number of recent analyst reports. Barclays cut their target price […]
• 04/18/2020

Ladenburg Thalmann Financial Services Inc. Lowers Stock Holdings in Mallinckrodt PLC (NYSE:MNK)

• Ladenburg Thalmann Financial Services Inc. lowered its holdings in Mallinckrodt PLC (NYSE:MNK) by 13.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 56,800 shares of the company’s stock after selling 8,832 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Mallinckrodt were worth $202,000 at the end of the most recent […]
• 04/18/2020

12 Short Squeeze Candidates To Watch

• One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky...
• 04/17/2020

How ANI Pharmaceuticals Plans to Take Down a Price-Gouging Giant

• A small-cap pharmaceuticals company may hold the solution to a nearly 100,000% drug price hike.
• 04/17/2020

Most Heavily Shorted Stocks - April 2020

• This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. Short-sellers are having a banner year with broad-
• 04/17/2020

Edison Issues Update On Silence Therapeutics (SLN)

• LONDON, UK / ACCESSWIRE / April 17, 2020 / The year 2019 marked a major turnaround for Silence (LSE:SLN), as it both ramped up its development activity, with the advancement of SLN124 for iron overload ...
• 04/17/2020

American Kidney Fund Coronavirus Emergency Fund Nears 7,000 Applications from Low-Income Kidney Patients; Recognizes Generous Corporate Donors Helping to Meet Unprecedented Need for Assistance

• ROCKVILLE, MD / ACCESSWIRE / April 16, 2020 / In its third week of providing emergency grants to low-income dialysis and post-transplant patients struggling to afford renal-friendly food, transportation, medications and medical supplies during the COVID-19 pandemic, the American Kidney Fund (AKF) today
• 04/16/2020

Mallinckrodt to Report Earnings Results for First Quarter 2020

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report first quarter 2020 earnings results for the period ended March 27, 2020 on Tuesday, May 5, 2020.
• 04/16/2020

Mallinckrodt to Report Earnings Results for First Quarter —…—…

• 04/16/2020

RemeGen candidate Fast Track'd for lupus

• The FDA has signed off on Fast Track status for Yantai, China-based RemeGen's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE).RC18 (telitacicept) is a recombinant TACI-F
• 04/15/2020

The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US

• Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs April 14) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Acceleron Pharma Inc (NASDAQ: XLRN) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Kala Pharmaceuticals
• 04/15/2020

Mallinckrodt announces publication Acthar Gel study in rheumatoid arthritis

• Mallinckrodt (NYSE:MNK) announces positive results from a Phase 4 clinical trial evaluating Acthar Gel (repository corticotropin injection) in patients with persistently active rheumatoid arthritis &#
• 04/15/2020

Mallinckrodt publishes findings from Phase 4 Acthar Gel study MNK

• Mallinckrodt publishes findings from Phase 4 Acthar Gel study MNK
• 04/15/2020

Mallinckrodt (NYSE:MNK) Stock Price Up 2.7%

• Mallinckrodt PLC (NYSE:MNK) shares rose 2.7% during trading on Monday . The stock traded as high as $3.96 and last traded at $3.76, approximately 147,218 shares were traded during trading. A decline of 98% from the average daily volume of 8,296,179 shares. The stock had previously closed at $3.66. Several equities research analysts have weighed […]
• 04/15/2020

Mallinckrodt Announces Publication of Data on Acthar® Gel (Repository Corticotropin Injection) from its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study in Rheumatoid Arthritis (RA) in Rheumatology and Therapy

• Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the publication of findings from its randomized, placebo-controlled, double-blind Phase 4 study to assess the safety and efficacy of Acthar® Gel (repository corticotropin injection, or RCI) in patients with persistently active rheumatoid arthritis (RA) despite treatment with stable background disease-modifying antirheumatic drugs (DMARDs) and low-dose glucocorticoids. Results of the study were recently published online in Rheumatology and Therapy, an open access peer-review journal. Preliminary findings from the study were presented at the European Congress of Rheumatology 2019 (EULAR) held in June.
• 04/15/2020

Opioid Induced Constipation (OIC) Industry Outlook, 2020-2025 - Rise in the Availability of Effective OIC Drugs, Growing Prevalence of Chronic Idiopathic Pains - ResearchAndMarkets.com

• The "Opioid Induced Constipation Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
• 04/15/2020

Mallinckrodt Highlights Publication Of Data On Acthar Gel (Repository Corticotropin Injection) From Its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study In Rheumatoid Arthritis (RA) In Rheumatology And Therapy

• 04/15/2020

Edited Transcript of SLN.L earnings conference call or presentation 14-Apr-20 12:00pm GMT

• Full Year 2019 Silence Therapeutics PLC Earnings Call
• 04/14/2020

Silence Therapeutics Final results for the year ended 31 December 2019

• Final results for the year ended 31 December 2019 April 14, 2020 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery,.
• 04/14/2020

Man Group plc Invests $110,000 in Mallinckrodt PLC (NYSE:MNK)

• Man Group plc purchased a new stake in shares of Mallinckrodt PLC (NYSE:MNK) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 31,638 shares of the company’s stock, valued at approximately $110,000. A number of other large investors have also recently added to […]
• 04/14/2020

Mallinckrodt (NYSE:MNK) Raised to "Hold" at ValuEngine

• Mallinckrodt (NYSE:MNK) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports. Several other equities research analysts have also commented on the stock. Barclays reduced their price target on shares of Mallinckrodt from $5.00 to $3.00 and […]
• 04/14/2020

Credit Suisse AG Sells 626,489 Shares of Mallinckrodt PLC (NYSE:MNK)

• Credit Suisse AG lessened its stake in shares of Mallinckrodt PLC (NYSE:MNK) by 98.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 11,181 shares of the company’s stock after selling 626,489 shares during the period. Credit Suisse AG’s holdings in Mallinckrodt were worth $38,000 as of its […]
• 04/12/2020

Mallinckrodt (NYSE:MNK) Shares Gap Up to $2.09

• Mallinckrodt PLC (NYSE:MNK)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $2.21, but opened at $2.09. Mallinckrodt shares last traded at $2.60, with a volume of 9,999,080 shares. A number of research firms have issued reports on MNK. ValuEngine cut Mallinckrodt from a “buy” rating to […]
• 04/10/2020

Global Opioid Induced Constipation (OIC) Market: Growth, Trends and Forecast (2020-2025)

• The "Opioid Induced Constipation Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
• 04/09/2020

Cubist Systematic Strategies LLC Has $638,000 Stake in Mallinckrodt PLC (NYSE:MNK)

• Cubist Systematic Strategies LLC cut its holdings in shares of Mallinckrodt PLC (NYSE:MNK) by 28.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,781 shares of the company’s stock after selling 72,443 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.22% […]
• 04/09/2020

Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates Again

• Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
• 04/08/2020

Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates Again

• Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
• 04/08/2020

U.S. Supreme Court Upholds Nitric Oxide Patent Win for Linde; Linde Commits to Support Inhaled Nitric Oxide Clinical Studies Relating to COVID-19

• GUILDFORD, UK / ACCESSWIRE / April 8, 2020 / Linde (NYSE:LIN; FWB:LIN), a leading global supplier of inhaled nitric oxide, is pleased with the decision by the U.S. Supreme Court declining to review the ...
• 04/08/2020

Mallinckrodt downsizes debt refinancing in new deal with Aurelius, Franklin MNK

• Mallinckrodt downsizes debt refinancing in new deal with Aurelius, Franklin MNK
• 04/08/2020

Mallinckrodt says Medicaid rebate penalties could hurt COVID-19 research

• Mallinckrodt Plc claims its research into a COVID-19 treatment would be hurt by allowing the U.S. government to extract "crippling penalties" from the drugmaker for underpaying rebates owed to state Medicaid programs after it hiked a drug's price.
• 04/07/2020

A 16% Leveraged Loan Is Painful But Necessary

• (Bloomberg Opinion) -- Backed into a corner by the coronavirus pandemic, Texas billionaire Tilman Fertitta is rolling the dice in the leveraged-loan market.Fertitta’s empire includes Golden Nugget casinos and restaurants under the Landry’s Inc. umbrella like Bubba Gump Shrimp Co., Morton’s The Steakhouse
• 04/07/2020

Drugmaker Mallinckrodt Downsizes Debt Refinancing

• Mallinckrodt said Tuesday the previous deal, which would have refinanced over $1.2 billion of its near-maturing debt, has been terminated. The pact was premised upon the pharmaceutical giant being able to raise a new term loan, but the deterioration of financial markets because of the coronavirus pandemic made it difficult for Mallinckrodt to obtain the new financing, according to people familiar with the matter.
• 04/07/2020

Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue

• Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
• 04/07/2020

Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue

• Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
• 04/07/2020

Mallinckrodt Stock Is Soaring on Refinancing of Debt

• The company filed notice with the Securities and Exchange Commission that it had refinanced $495 million in debt due this year.
• 04/07/2020

BRIEF-Mallinckrodt PLC Files For 4.875% Senior Notes Due 2020

• Mallinckrodt Plc:
• 04/07/2020

Barron's on MarketWatch: Could COVID-19 bring generic-drug making back to U.S.?

• SVB Leerink analyst Ami Fadia says the pandemic could bring some relief to beaten-down generic-drug companies.
• 04/07/2020

Covid-19 Could Bring Generic Drug Manufacturing Back to the U.S., Analyst Writes

• SVB Leerink analyst Ami Fadia says the pandemic could bring some relief to beaten-down generic-drug companies.
• 04/07/2020

Mallinckrodt trading resumes MNK

• Mallinckrodt trading resumes MNK
• 04/07/2020

Mallinckrodt trading halted, news pending MNK

• Mallinckrodt trading halted, news pending MNK
• 04/07/2020

Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?

• Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
• 04/07/2020

Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?

• Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
• 04/07/2020

CLARET ASSET MANAGEMENT Corp Has $149,000 Holdings in Mallinckrodt PLC (NYSE:MNK)

• CLARET ASSET MANAGEMENT Corp lessened its stake in Mallinckrodt PLC (NYSE:MNK) by 9.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,407 shares of the company’s stock after selling 7,837 shares during the quarter. CLARET ASSET MANAGEMENT Corp owned approximately […]
• 04/07/2020

Mallinckrodt Shares Resume Trade, Tick To Pre-Market High Of $2.05, Pullback To $1.90 Level

• 04/07/2020

Mallinckrodt: Back To The Negotiating Table

• Negative CMS outcome and lenders backing out of financing have dented the prospect of achieving the planned opioid settlement. $610 million bond repayment is ma
• 04/06/2020

Mallinckrodt subsidiary initiates rolling submission of StrataGraft BLA to FDA MNK

• Mallinckrodt subsidiary initiates rolling submission of StrataGraft BLA to FDA MNK
• 04/06/2020

BRIEF-Mallinckrodt Initiates Rolling Submission Of Biologics License Application For Stratagraft Regenerative Skin Tissue To U.S. FDA

• Mallinckrodt Plc:
• 04/06/2020

Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration

• Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval to market StrataGraft®, a regenerative skin tissue therapy, for the treatment of adult patients with deep partial-thickness thermal burns. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been established by the FDA.
• 04/06/2020

Mallinckrodt (NYSE:MNK) Price Target Cut to $3.00 by Analysts at Barclays

• Mallinckrodt (NYSE:MNK) had its target price reduced by Barclays from $5.00 to $3.00 in a research note released on Thursday, BenzingaRatingsTable reports. They currently have an equal weight rating on the stock. A number of other research analysts have also recently commented on MNK. Bank of America boosted their target price on shares of Mallinckrodt […]
• 04/06/2020

Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® ...

• 04/06/2020